Risk factors for the occurrence of multidrug-resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis treatment in East Shoa, Ethiopia
- PMID: 29606112
- PMCID: PMC5879744
- DOI: 10.1186/s12889-018-5371-3
Risk factors for the occurrence of multidrug-resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis treatment in East Shoa, Ethiopia
Abstract
Background: Multidrug-resistant tuberculosis (MDR-TB) is resistant to the two main first-line anti-tuberculosis drugs: rifampicin and isoniazid. It is a major threat to public health worldwide. The objective of this study was to assess the potential risk factors for multidrug-resistant tuberculosis among patients undergoing MDR-TB treatment at two community hospitals in Ethiopia.
Methods: A case-control study design was conducted from February 1, 2016, to April 29, 2016. TB-positive patients with MDR-TB and non-MDR-TB were considered as cases and controls, respectively. A total of 219 study participants were included in the study. An interviewer-administered structured questionnaire was used to collect primary data from the patients, and a checklist was used to collect data from the clinical records. Bivariate and multivariate logistic regression analyses were used to assess the potential risk factors for the occurrence of MDR-TB.
Results: The odds of developing MDR-TB were higher in patients previously treated with anti-TB drugs (odds ratio [OR] = 6.1, 95%CI: 2.92-12.62, P < 0.001), those with a history of contact with known TB patients (OR = 2.1, 95%CI: 1.04-4.43, P < 0.001), those living in a rural setting (OR = 5.6, 95%CI: 2.14-14.46, P = 0.001), those with a history of alcohol consumption (OR = 4.3, 95%CI: 2.29-10.49, P < 0.001) and those without a job (OR = 2.4, 95%CI: 1.06-5.42, P = 0.001).
Conclusions: The study revealed that contact with known TB patients, previous TB treatment, residence area, lack of a job, and alcohol consumption were potential risk factors for the occurrence of MDR-TB. Enhancing public health education, intensifying directly observed therapy programmes for all TB patients and designing control strategies are recommended.
Keywords: Anti-TB drugs; MDR-TB; Risk factors; TB.
Conflict of interest statement
Ethics approval and consent to participate
This study was approved by the Oromia Health Bureau (Ref no. BEEFO/1–8/1239). A statement about the purpose of the study was read and explained to each study participant. Only those who gave verbal consent to participate in the study were included in the study.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Similar articles
-
Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State.Afr Health Sci. 2015 Jun;15(2):368-77. doi: 10.4314/ahs.v15i2.9. Afr Health Sci. 2015. PMID: 26124781 Free PMC article.
-
Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study.Ann Clin Microbiol Antimicrob. 2018 Jul 3;17(1):30. doi: 10.1186/s12941-018-0283-8. Ann Clin Microbiol Antimicrob. 2018. PMID: 29970076 Free PMC article.
-
Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi Zone, Oromia Regional State, Central Ethiopia.BMC Public Health. 2016 Jul 18;16:593. doi: 10.1186/s12889-016-3210-y. BMC Public Health. 2016. PMID: 27430266 Free PMC article.
-
Multi-drug resistant tuberculosis burden and risk factors: an update.Kathmandu Univ Med J (KUMJ). 2010 Jan-Mar;8(29):116-25. doi: 10.3126/kumj.v8i1.3234. Kathmandu Univ Med J (KUMJ). 2010. PMID: 21209520 Review.
-
Drug-resistant tuberculosis in Ethiopia: problem scenarios and recommendation.Ethiop Med J. 2002 Jan;40(1):79-86. Ethiop Med J. 2002. PMID: 12240570 Review.
Cited by
-
Determinants of Multidrug-Resistant Mycobacterium tuberculosis Infection: A Multicenter Study from Southern Ethiopia.Infect Drug Resist. 2022 Jul 5;15:3523-3535. doi: 10.2147/IDR.S363628. eCollection 2022. Infect Drug Resist. 2022. PMID: 35818450 Free PMC article.
-
Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.BMC Infect Dis. 2019 Sep 6;19(1):779. doi: 10.1186/s12879-019-4375-7. BMC Infect Dis. 2019. PMID: 31492099 Free PMC article.
-
Magnitude of Multidrug Resistance and Associated Factors of Pulmonary Tuberculosis Among Adult Smear Positive Patients in Eastern Ethiopia.Infect Drug Resist. 2021 Oct 28;14:4493-4500. doi: 10.2147/IDR.S326798. eCollection 2021. Infect Drug Resist. 2021. PMID: 34737589 Free PMC article.
-
Prevalence of Rifampicin resistance tuberculosis among presumptive tuberculosis patients in Egypt-2021: a national health facility-based survey.BMC Infect Dis. 2024 Feb 15;24(1):210. doi: 10.1186/s12879-023-08807-7. BMC Infect Dis. 2024. PMID: 38360617 Free PMC article.
-
Predictors of Multidrug-Resistant Tuberculosis (MDR-TB) in Sudan.Antibiotics (Basel). 2019 Jul 9;8(3):90. doi: 10.3390/antibiotics8030090. Antibiotics (Basel). 2019. PMID: 31323935 Free PMC article.
References
-
- World health organization . Global Tuberculosis report. Geneva: World health organization; 2015.
-
- European center for disease control . Tuberculosis surveillance and monitoring in Europe. Surveillance report. Stockholm: European center for disease control; 2016.
-
- World health organization . Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. The end TB strategy. 2014. - PubMed
-
- World health organization . World Health Organization: global tuberculosis control. Geneva: World health organization; 2013.
-
- Federal Ministry of Health . Guideline for program and clinical management of drug resistant tuberculosis. 2009.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous